Sage Therapeutics, Inc. has announced the cessation of its collaboration with Biogen regarding the SAGE-324 program, a move that follows the recent unfavorable outcomes of the Phase 2 KINETIC 2 Study. This decision marks a significant turn in the investigational treatment landscape for essential tremor (ET), as SAGE-324 was one of the promising candidates being explored for this condition.
The KINETIC 2 Study sought to evaluate the efficacy of SAGE-324 (also referred to as BIIB124) in chronic essential tremor. The primary focus of the trial was to assess whether the drug could produce a statistically significant dose-response relationship on the Essential Tremor Rating Assessment Scale (TETRAS) from the baseline measurement to Day 91 of the study. However, the topline results indicated no significant therapeutic advantage, leading to a decision by Biogen to terminate its rights under the collaboration and license agreement specific to this program.
Despite the discontinuation of SAGE-324 in the ET space, Sage Therapeutics and Biogen will maintain their partnership for ZURZUVAE, another investigational treatment. The commitment to continue collaboration on ZURZUVAE suggests that there remains a strong conviction in the potential of other therapies being developed by Sage, which focus on brain health.
The discontinuation of the SAGE-324 program highlights the challenges and complexities inherent in drug development, particularly for neurological disorders like essential tremor. As Sage Therapeutics moves forward, it will also be participating in a series of investor conferences in May 2024, including the RBC Capital Markets Global Healthcare Conference in New York and the BofA Securities Healthcare Conference in Las Vegas. These engagements will likely provide the company opportunities to discuss potential future directions and strategies in the face of these recent setbacks.
In conclusion, while the cessation of the SAGE-324 program is a significant disappointment in the quest for effective treatments for essential tremor, it underscores the importance of ongoing research and development in the biopharmaceutical industry. Sage Therapeutics continues to seek innovative solutions for neurological conditions, affirming its commitment to enhancing brain health despite the hurdles faced with SAGE-324.
Comments